74034-09-6

Basic information

• Product Name: 1-deoxy-N-acetylglucosamine
• Synonyms: 1-deoxy-N-acetylglucosamine
• CAS NO: 74034-09-6
• Molecular Formula: C₈H₁₅NO₅
• Molecular Weight: 205.21
• Mol File: 74034-09-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-deoxy-N-acetylglucosamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-deoxy-N-acetylglucosamine(74034-09-6)
• EPA Substance Registry System: 1-deoxy-N-acetylglucosamine(74034-09-6)

Safety Data

• Hazardous Substances Data: 74034-09-6(Hazardous Substances Data)

Upstream product

• 4271-28-7 2-acetylamino-2-deoxy-D-glucitol 
• 14131-68-1 N-acetyl-D-glucosamine 
• 3068-34-6 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride 
• 22854-00-8 2-methyl-(1,2-dideoxy-α-D-glucopyranoso)-[2,1-d]-2-oxazoline 
• 65372-02-3 2-methyl-(3,4,6-tri-O-benzyl-1,2-dideoxy-α-D-glucopyrano)-<2,1-d>-2-oxazoline 
• 3068-34-6 Acetic acid (2R,3S,4R,5R,6R)-3-acetoxy-2-acetoxymethyl-5-acetylamino-6-chloro-tetrahydro-pyran-4-yl ester 
• 74080-14-1 2-acetamido-3,4,6-tri-O-acetyl-1,5-anhydro-2-deoxy-D-glucopyranose 

Downstream Products

• 81638-42-8 2-acetamido-1,5-anhydro-4,6-O-benzylidene-2-deoxy-D-glucitol 
• 3055-51-4 benzyl 2-deoxy-2-(N-acetylamino)-D-glucopyranoside 
• 120903-68-6 N-[(2S,3R,4R,5S,6R)-2-Benzyloxy-6-(tert-butyl-dimethyl-silanyloxymethyl)-4,5-dihydroxy-tetrahydro-pyran-3-yl]-acetamide 
• 120903-74-4 N-Benzyl-N-((1S,2R,3S,6S)-2,3-bis-benzyloxy-6-hydroxy-4-oxo-cyclohexyl)-acetamide 
• 120903-73-3 N-Benzyl-N-((2S,3R,4R,5S)-2,4,5-tris-benzyloxy-6-methylene-tetrahydro-pyran-3-yl)-acetamide 
• 120903-72-2 N-Benzyl-N-((2S,3R,4R,5S,6S)-2,4,5-tris-benzyloxy-6-iodomethyl-tetrahydro-pyran-3-yl)-acetamide 
• 120903-70-0 N-Benzyl-N-((2S,3R,4R,5S,6R)-2,4,5-tris-benzyloxy-6-hydroxymethyl-tetrahydro-pyran-3-yl)-acetamide 
• 120903-69-7 N-Benzyl-N-[(2S,3R,4R,5S,6R)-2,4,5-tris-benzyloxy-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-pyran-3-yl]-acetamide 
• 120903-71-1 Methanesulfonic acid (2R,3S,4R,5R,6S)-5-(acetyl-benzyl-amino)-3,4,6-tris-benzyloxy-tetrahydro-pyran-2-ylmethyl ester 
• 85080-90-6 N-((2R,4aR,7S,8R,8aS)-8-Hydroxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yl)-acetamide 
• 81638-47-3 2-acetamido-1,5-anhydro-6-O-(2-behenoyloxyisobutyryl)-2-deoxy-3-O-<(R)-2-propanoyl-L-alanyl-D-isoglutamine benzyl ester>-D-glucitol 
• 81638-44-0 2-acetamido-1,5-anhydro-4,6-O-benzylidene-2-deoxy-3-O-<(R)-2-propanoyl-L-alanyl-D-isoglutamine benzyl ester>-D-glucitol 
• 81638-46-2 2-acetamido-1,5-anhydro-2-deoxy-3-O-<(R)-2-propanoyl-L-alanyl-D-isoglutamine benzyl ester>-D-glucitol 
• 81638-43-9 2-acetamido-1,5-anhydro-4,6-O-benzylidene-3-O-<(R)-1-carboxyethyl>-2-deoxy-D-glucitol 

Relevant articles and documents

On the hydrogenation of glycosyl oxazolines

An investigation is undertaken into the propensity of glycosyl oxazolines to undergo reductive cleavage by catalytic hydrogenation. Results indicate that the protecting groups on carbohydrate hydroxyl groups modulate the rate of glycosyl oxazoline reducti

Synthesis of N-[2-O-(2-acetamido-1,5-anhydro-2,3-dideoxy-D-glucitol-3-yl) -D-lactoyl]-L-alanyl-D-isoglutamine (1-deoxy-MDP) and some of its lipophilic analogs, and their immunoadjuvant activities

-

COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION

The present disclosure relates to compounds and methods for treating symptoms or sequelae resulting from viral infection, including influenza, rhinovirus, or betacoronavirus infection, such as human coronaviruses such as SARS coronaviruses, MERS coronaviruses, and COVID-19, including Acute Respiratory Distress Syndrome (ARDS) associated with the viral infection.

Design, Synthesis, and Preliminary Biological Evaluation of GlcNAc-6P Analogues for the Modulation of Phosphoacetylglucosamine Mutase 1 (AGM1/PGM3)

A library of GlcNAc 6- or 1-phosphate analogues was designed, and each compound was evaluated computationally through docking studies for its binding affinity to AGM1/PGM3. The compounds with the highest binding affinity, as ranked through a docking score, were synthesised and screened for their ability to inhibit the production of UDP-GlcNAc. A glycofused oxazoline analogue showed good inhibition, and gave significant results in vitro.